参考文献/References:
[1] HIGH K A,RONCAROLO M G.Gene therapy[J].The New England Journal of Medicine,2019,381(5):455-464.DOI:10.1056/NEJMra1706910.
[2] 王晓,黄晓平,黎玲,等.氧化应激促进重组腺相关病毒2型体外转导分析[J].华侨大学学报(自然科学版),2022,43(4):489-497.DOI:10.11830/ISSN.1000-5013.202201036.
[3] 王晓,黄晓平,黎玲,等.重组腺相关病毒基因药物三种滴度的比较与分析[J].华侨大学学报(自然科学版),2021,42(4):507-511.DOI:10.11830/ISSN.1000-5013.202010006.
[4] DUNBAR C E,HIGH K A,JOUNG J K,et al.Gene therapy comes of age[J].Science,2018,359(6372):eaan4672.DOI:10.1126/science.aan4672.
[5] MENDELL J R,AL-ZAIDY S,SHELL R,et al.Single-dose gene-replacement therapy for spinal muscular[J].The New England Journal of Medicine,2017,377(18):1713-1722.DOI:10.1056/NEJMoa1706198.
[6] LI Chengwen,SAMULSKI R J.Engineering adeno-associated virus vectors for gene therapy[J].Nature Reviews Genetics,2020,21(4):255-272.DOI:10.1002/0470025077.chap69.
[7] JACOBSON S G,CIDECIYAN A V,ROMAN A J,et al.Improvement and decline in vision with gene therapy in childhood blindness[J].The New England Journal of Medicine,2015,372(20):1920-1926.DOI:10.1056/NEJMoa1412965.
[8] VANDENDRIESSCHE T,PIPE S W,PIERCE G F,et al.First conditional marketing authorization approval in the European Union for hemophilia “A” gene therapy[J].Molecular Therapy: The Journal of the American Society of Gene Therapy,2022,30(11):3335-3336.DOI:10.1016/j.ymthe.2022.09.020.
[9] PHILIPPIDIS A.Novartis confirms deaths of two patients treated with gene therapy zolgensma[J].Human Gene Therapy,2022,33(17/18):842-844.DOI:10.1089/hum.2022.29216.bfs.
[10] PHILIPPIDIS A.Fourth boy dies in clinical trial of Astellas’ AT132[J].Human Gene Therapy,2021,32(19/20):1008-1010.DOI:10.1089/hum.2021.29182.bfs.
[11] BATTY P,LILLICRAP D.Hemophilia gene therapy: Approaching the first licensed product[J].Hemasphere,2021,5(3):e540.DOI:10.1097/HS9.0000000000000540.
[12] PIERCE G F.Uncertainty in an era of transformative therapy for haemophilia: Addressing the unknowns[J].Haemophilia,2021,27(S3):103-113.DOI:10.1111/hae.14023.
[13] WESTHAUS A,CABANES-CREUS M,RYBICKI A,et al.High-throughput in vitro, ex vivo, and in vivo screen of adeno-associated virus vectors based on physical and functional transduction[J].Human Gene Therapy,2020,31(9/10):575-589.DOI:10.1089/hum.2019.264.
[14] WANG Jinhui,XIE Jing,LU Hui,et al.Existence of transient functional double-stranded DNA intermediates during recombinant AAV transduction[J].Proceedings of the National Academy of Sciences of the United States of America,2007,104(32):13104-13109.DOI:10.1073/pnas.0702778104.
[15] LANG J F,TOULMIN S A,BRIDA K L,et al.Standard screening methods underreport AAV-mediated transduction and gene editing[J].Nature Communications,2019,10(1):3415.DOI:10.1038/s41467-019-11321-7.
[16] DEVERMAN B E,PRAVDO P L,SIMPSON B P,et al.Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain[J].Nature Biotechnology,2016,34(2):204-209.DOI:10.1038/nbt.3440.
[17] HILLESTAD M L,GUENZEL A J,NATH K A,et al.A vector-host system to fingerprint virus tropism[J].Human Gene Therapy,2012,23(10):1116-1126.DOI:10.1089/hum.2011.116.
[18] CHAN K Y,JANG M J,YOO B B,et al.Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems[J].Nature Neuroscience,2017,20(8):1172-1179.DOI:10.1038/nn.4593.
[19] 王启钊,吕颖慧,刁勇,等.重组腺相关病毒载体的泛素化机制及其应用[J].浙江大学学报(医学版),2012,41(5):586-591.DOI:10.3785/j.issn.1008-9292.2012.05.020.
[20] DOUAR A,POULARD K,STOCKHOLM D,et al.Intracellular trafficking of adeno-associated virus vectors: Routing to the late endosomal compartment and proteasome degradation[J].Journal of Virology,2001,75(4):1824-1833.DOI:10.1128/JVI.75.4.1824-1833.2001.
[21] LISOWSKI L,DANE A P,CHU K,et al.Selection and evaluation of clinically relevant AAV variants in a xenograft liver model[J].Nature,2014,506(7488):382-386.DOI:10.1038/nature12875.
[22] TABEBORDBAR M,LAGERBORG K A,STANTON A,et al.Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species[J].Cell,2021,184(19):4919-4938.DOI:10.1016/j.cell.2021.08.028.
[23] 刁勇,许瑞安.重组腺相关病毒载体诱导的天然免疫反应及机制[J].微生物学报,2012,52(5):550-557.
[24] KONKLE B A,WALSH C E,ESCOBAR M A,et al.BAX 335 hemophilia B gene therapy clinical trial results: Potential impact of CpG sequences on gene expression[J].Blood,2021,137(6):763-774.DOI:10.1182/blood.2019004625.
[25] BROWN H C,ZAKAS P M,GEORGE S N,et al.Target-cell-directed bioengineering approaches for gene therapy of hemophilia A[J].Molecular Therapy: Methods and Clinical Development,2018,9:57-69.DOI:10.1016/j.omtm.2018.01.004.
[26] 刁勇,王启钊,肖卫东,等.重组腺相关病毒基因药物的细胞免疫毒性及对策[J].药学学报,2010,45(9):1071-1077.
[27] CABANES-CREUS M,NAVARRO R G,ZHU Erhua,et al.Novel human liver-tropic AAV variants definetransferable domains that markedly enhance the human tropism of AAV7 and AAV8[J].Molecular Therapy: Methods and Clinical Development,2022,24:88-101.DOI:10.1016/j.omtm.2021.11.011.
[28] LIN Chen,JIANG Meng,LIU Ling,et al.Imaging of individual transcripts by amplification-based single-molecule fluorescence in situ hybridization[J].New Biotechnology,2021,61:116-123.DOI:10.1016/j.nbt.2020.12.001.
[29] AIZARANI N,SAVIANO A,SAGAR,et al.A human liver cell atlas reveals heterogeneity and epithelial progenitors[J].Nature,2019,572(7768):199-204.DOI:10.1038/s41586-019-1373-2.
[30] ZOLOTUKHIN I,MARKUSIC D M,PALASCHAK B,et al.Potential for cellular stress response to hepatic factor Ⅷ expression from AAV vector[J].Molecular Therapy: Methods and Clinical Development,2016,3:16063.DOI:10.1038/mtm.2016.63.
[31] MERLIN S,FAMà R,BORRONI E,et al.FⅧ expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice[J].Blood Advances,2019,3(5):825-838.DOI:10.1182/bloodadvances.2018027979.
[32] YU Yuan,ZENG Zhiwei,XIE Danlin,et al.Interneuron origin and molecular diversity in the human fetal brain[J].Nature Neuroscience,2021,24(12):1745-1756.DOI:10.1038/s41593-021-00940-3.